1-3 of 3
Herbert Struemper
Close
Sort by
Journal Articles

Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3

Geraldine Ferron-Brady, Adekemi Taylor, Josh Kaullen, Kishore Polireddy, Astrid McKeown, Neal Sule, Herbert Struemper
Journal: Blood
Blood (2023) 142 (Supplement 1): 6730.
https://doi.org/10.1182/blood-2023-178026
Published: 2023
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,

Michael J. Robertson, MD, John Bauman, Olivia Gardner, Zdenka Jonak, Herbert Struemper, Fiona Germaschewski, Kevin M. Koch, Sharon Murray, Jill Weisenbach, RN, John Toso, MD, MSc
Journal: Blood
Blood (2011) 118 (21): 3697.
https://doi.org/10.1182/blood.V118.21.3697.3697
Published: 2011